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Abstract Previous studies showed strong correla-
tions between low ﬁngertip temperature rebound
measured by digital thermal monitoring (DTM)
during a 5 min arm-cuff induced reactive hyperemia
and both the Framingham Risk Score (FRS), and
coronary artery calciﬁcation (CAC) in asymptomatic
populations. This study evaluates the correlation
between DTM and coronary artery disease (CAD)
measured by CT angiography (CTA) in symptomatic
patients. It also investigates the correlation between
CTA and a new index of neurovascular reactivity
measured by DTM. 129 patients, age 63 ± 9 years,
68% male, underwent DTM, CAC and CTA.
Adjusted DTM indices in the occluded arm were
calculated: temperature rebound: aTR and area
under the temperature curve aTMP-AUC. DTM
neurovascular reactivity (NVR) index was measured
based on increased ﬁngertip temperature in the non-
occluded arm. Obstructive CAD was deﬁned as
C50% luminal stenosis, and normal as no stenosis
and CAC = 0. Baseline ﬁngertip temperature was not
different across the groups. However, all DTM
indices of vascular and neurovascular reactivity
signiﬁcantly decreased from normal to non-obstruc-
tive to obstructive CAD [(aTR 1.77 ± 1.18 to
1.24 ± 1.14 to 0.94 ± 0.92) (P = 0.009), (aTMP-
AUC: 355.6 ± 242.4 to 277.4 ± 182.4 to 184.4 ±
171.2) (P = 0.001), (NVR: 161.5 ± 147.4 to 77.6 ±
88.2 to 48.8 ± 63.8) (P = 0.015)]. After adjusting
for risk factors, the odds ratio for obstructive
CAD compared to normal in the lowest versus two
upper tertiles of FRS, aTR, aTMP-AUC, and NVR
were 2.41 (1.02–5.93), P = 0.05, 8.67 (2.6–9.4),
P = 0.001, 11.62 (5.1–28.7), P = 0.001, and 3.58
(1.09–11.69), P = 0.01, respectively. DTM indices
and FRS combined resulted in a ROC curve area of
0.88 for the prediction of obstructive CAD. In
patients suspected of CAD, low ﬁngertip temperature
rebound measured by DTM signiﬁcantly predicted
CTA-diagnosed obstructive disease.
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Despite major advances in the treatment of coronary
artery disease (CAD), a large number of apparently
healthy people die suddenly of a heart attack
without prior symptoms and do not beneﬁt from
existing preventive therapies. Therefore, early detec-
tion and treatment of at risk individuals for primary
prevention of CAD is of grave importance. Tradi-
tional cardiovascular assessment methods such as
the Framingham Risk Score (FRS), which rely
solely on risk factor measurement, are useful for
long term prediction of risk at population levels, but
are grossly inaccurate and insufﬁcient for individu-
alized assessment of risk [1–3]. Measurement of risk
factors such as high cholesterol does not show the
vascular health of an individual. Therefore, non-
invasive, individualized, direct assessment of vascu-
lar health that is superior to the FRS is needed.
Multiple noninvasive imaging modalities (ultra-
sound, computed tomography, magnetic resonance
imaging) can aid in cardiovascular risk assessment
but are not feasible (due to high cost and potential
adverse effects) for screening healthy populations
and need for repeated uses in primary prevention
settings. A low-cost and easy-to-perform test capa-
ble of direct measurement of vascular function that
would provide additive value to FRS is, therefore,
needed. Such a test may also complement vascular
structural imaging tests such as coronary artery
calcium (CAC) score and carotid intima-media
thickness [4–6].
Vascular dysfunction is generally considered a
key initial event in the atherosclerotic process which
is a systemic disorder local manifestation. Numerous
studies have shown that functional changes in
arteries precede the development of structural
changes and also reverse more quickly in response
to therapies [7, 8]. Fingertip Digital Thermal
Monitoring (DTM) of vascular reactivity is a new
non-invasive, operator-independent test based on
changes in ﬁngertip temperature during and after
arm cuff occlusion. DTM has been shown to
correlate with the burden of subclinical coronary
atherosclerosis in asymptomatic patients, measured
by coronary artery calcium and nuclear perfusion
imaging [9–12]. The present study was designed to
evaluate whether vascular dysfunction measured by
DTM correlates with the presence and extent of
CAD diagnosed by computed tomography angiog-
raphy (CTA) in patients with suspected coronary
artery disease (CAD).
Methods
Subjects and study design
The study population includes 129 consecutive
patients with suspected CAD who were referred to
the CTA laboratory: 68 with typical angina, 39 with
atypical angina, 15 with equivocal exercise stress
tests, and seven with shortness of breath. All subjects
underwent coronary artery calcium (CAC) scanning,
CTA and DTM. Subjects over 35 years were eligible
to participate. Patients with established cardiovascu-
lar disease, stroke, diabetic retinopathy, end-stage
renal disease, Raynaud’s syndrome, infection, cancer,
immunosuppression, systemic inﬂammation, and
end-stage renal or liver disease were excluded. Body
mass index, waist circumference, blood pressure,
fasting blood glucose, and lipid proﬁle were obtained
by standard techniques. Risk factors were determined
and Framingham risk score (FRS) calculated [13].
Study protocols
Digital thermal monitoring of vascular reactivity
All DTM measurements were performed in the
morning in a quiet, dimmed room at a controlled
ambient temperature between 23.5 and 25.0C.
Female participants were examined during the fol-
licular phase of their menstrual cycle. Studies were
conducted after an overnight fast of at least 10 h
(water was permitted) and abstinence from tobacco,
alcohol, caffeine, vasoactive medications, exercise,
high-fat foods and vitamin C. The measurements
were obtained with the subjects supine and after
30 min of rest. Each patient’s blood pressure in the
control arm was recorded in a sitting position 5 min
before the DTM test (IntelliSense
 Professional
Digital Blood Pressure Monitor, HEM-907XL, Om-
ron Inc, Illinois). DTM of both hands was obtained
during 5 min stabilization, 5 min cuff inﬂation to
50 mmHg greater than systolic blood pressure, and
5 min deﬂation using an automated, operator-inde-
pendent protocol (VENDYS, Endothelix Inc.,
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123Houston, TX). Thermal changes during a 5 min arm-
cuff induced reactive hyperemia test were monitored
continuously in the ﬁngertip of both the occluded and
non-occluded arms using VENDYS software. The
device consists of a computer based thermometry
system (0.006C thermal resolution) with two ﬁnger-
tip RTD (Resistance Temperature Detector) fast
response probes designed to minimize the skin-probe
contact area and ﬁngertip pressure, attached to the
pulp of the index ﬁnger on both hands. The system
includes a common automated sphygmomanometer
cuff, cuff-inﬂation pump, and release valve to permit
noninvasive measurement of arterial pressure and the
control of occlusive hyperemia. Dual channel tem-
perature data are simultaneously acquired at a 1 Hz
sampling rate.
DTM indices
Figure 1a shows DTM indices of vascular reactivity
measured based on the amount of temperature
rebound (TR) and area under the temperature curve
(TMP-AUC) in the ﬁngertip of the occluded arm.
Neurovascular reactivity (NVR), thermal changes
in non-occluded arm during and after reactive
hyperemia, was similar in the arm and ﬁnger cuff
occlusive reactive hyperemia procedure (r = 0.96,
P = 0.0001). Infrared Imaging shows the changes in
new DTM index of neurovascular reactivity (NVR)
measured based on the area under the ﬁngertip
temperature curve in the non-occluded arm during
reactive hyperemia procedure. The ﬁngertip temper-
ature changes in the occluded arm are shown in red
line and the blue line shows temperature changes in
the non-occluded arm. Figure 1b illustrated a good
vascular reactivity, TR and TMP-AUC, (Top) and
good neurovascular reactivity, NVR (Bottom).
Adjustment of DTM indices
aTR and aTMP-AUC were computed to account for
variations in both test site conditions, such as ambient
temperature and air velocity [14], and variable patient
features, such as ﬁnger size, ﬁnger thermal physical
properties and temperature drop from inlet arteries to
venous return [15–19]. A lumped capacity energy
Fig. 1 Skin temperature changes during cuff-reactive hyper-
emia, as shown by infrared imaging and digital thermal
monitoring (DTM). Infrared imaging reconﬁrms increase in
non-occluded arm ﬁngertip temperature during reactive hyper-
emia procedure. Both arm and ﬁnger cuff reactive hyperemia
had similar neurovascular reactivity (r = 0.96, P = 0.0001)
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123balance for a ﬁnger in a room with air movement
shows that the ﬁnger temperature under steady state
conditions depends upon the size and orientation of
the ﬁnger, the ambient temperature and air ﬂow
conditions, and the ﬁnger blood ﬂow rate and
temperature drop from inlet arteries to venous return.
In addition, the fall of ﬁnger surface temperature
during complete occlusion of the arteries supplying
blood ﬂow depends upon the size and thermal
physical properties of the ﬁnger.
From measurements of the steady state ﬁnger
surface temperature and the transient response of
surface temperature to occlusion, the ﬁnger thermal
time constant and the heat loss characteristics to the
surrounding room can be determined. This informa-
tion can be used to predict the ﬁnger temperature
recovery after release of occlusion for the case of
zero vascular reactivity in response to the occlusion.
That is, the solution to the temperature recovery
assuming a step change in blood perfusion rate back
to the original steady state value before occlusion can
be computed. By using this solution as a baseline for
comparison, the temperature increase above the zero
reactivity case can be computed and used as an
indication of the amount of reactive hyperemia
present after release of occlusion.
One of the advantages of this approach is that the
ambient temperature and ambient air ﬂow conditions
are accounted for in the zero reactivity predictions
and, thus, their effects on the ﬁnal results are reduced.
Also, the resulting signal has a well deﬁned maxi-
mum and area under the curve, since the difference
signal starts and ends at zero temperature difference.
aTR and aTMP-AUC provide indicators of the
amount of reactive hyperemia present during the
recovery from occlusion.
Coronary artery calcium scanning
The studies were performed with an E-Speed electron
beam scanner (EBCT) (GE-Imatron, South San Fran-
cisco, CA, USA). The coronary arteries were imaged
with 30–40 contiguous 3 mm slices during end-
diastole using ECG-triggering during a 35 s breath
hold.CAC was consideredpresent inacoronaryartery
when a density of [130 Hounsﬁeld units (HU) was
detected in C3 contiguous pixels ([1m m
2) overlying
that coronary artery; it was quantiﬁed using the
previously described Agatston scoring method [20].
Computed tomography angiography
Beta blockers were administered for heart rates
greater than 65 bpm. Using a dual-head power
injector (Stellant, Medrad, Indianola, PA), cardiac
CTA was performed with a tri-phasic consecutive
injection sequence beginning with 50 ml nonionic
IV contrast material (Omnipaque, Amersham
Health) injected at a rate of 5 ml/s followed by
50 ml of a mixture of 60% contrast and normal
saline and ending with a 50 ml ﬂush of normal
saline. Contrast was injected through an 18- to
20-gauge angiocatheter in an antecubital vein. All
studies were performed by a 64 multi-detector
computed tomography (MDCT) scanner (Lightspeed
VCT, General Electric Healthcare Technologies,
Milwaukee, WI). The following imaging and recon-
struction parameters were applied: data acquisi-
tion collimation 0.625 mm 9 64 = 4 cm; 140 kVp;
300–600 mAs; pitch 0.18–0.24; rotation time 0.35 s;
slice width 0.625 mm; ﬁeld of view 50 cm; matrix
512 9 512. Cardiac data were reconstructed retro-
spectively at 0–90% of the R–R interval at
0.625 mm. Coronary vessels were reviewed on the
workstation using commercial cardiac volume mod-
els (AW Volume Share
TM, GE Medical Systems,
Milwaukee, WI). Two skilled cardiologists blinded
to the clinical data assessed the coronary arteries
separately. Discrepancies in interpretation between
the reviewers were resolved by consensus (three
cases). The coronary arteries were segmented
according to American Heart Association guidelines,
based on 16-segment classiﬁcations for evaluation of
coronary artery stenosis. Each vessel segment was
assessed as normal: no stenosis and CAC score = 0,
mild CAD: 1–30% stenosis, moderate CAD: 31–
69% stenosis, or severe CAD: C70% stenosis. Each
segment was also classiﬁed as normal, non-obstruc-
tive CAD: luminal stenosis \50%, and obstructive
CAD: luminal stenosis C50%.
Statistical analysis
Mean ± SD and proportions were used to summarize
the characteristics of the study sample. Continuous
variables were compared by ANOVA, and categor-
ical variables were compared by the Kruskal-Wallis
non-parametric ANOVA. Multivariate linear and
logistic regression analyses were employed to assess
728 Int J Cardiovasc Imaging (2009) 25:725–738
123the relationship of extent of CTA-diagnosed CAD
and DTM indices, with and without adjustment for
conventional cardiovascular risk factors, as well as
for left ventricular ejection fraction. ROC curves
were constructed and the area under the ROC curve
(AUC) was calculated to predict the ability of each
model to detect obstructive CAD. All statistical
analyses were performed with SAS version 9.1 (SAS
Institute Inc, Cary, NC, http://www.sas.com). The
level of signiﬁcance was set at P\0.05 (two-tailed).
The study protocol and consent form were approved
by IRB Committee Board of Los Angeles Biomedical
Research Institute at Harbor UCLA Medical Center,
Torrance, CA.
Results
Characteristics of the study population are high-
lighted in Table 1 according to the extent of CAD
among the 129 consecutive participants (age
63 ± 9 years, 68% male). One hundred and one
(78.3%) had CTA-diagnosed CAD (27 with obstruc-
tive CAD and 74 with non-obstructive CAD). There
were no signiﬁcant statistical differences between
normal, non-obstructive and obstructive CAD cohorts
in age, gender, hypertension, hypercholesterolemia,
diabetes, smoking status, family history of premature
CHD, left ventricular ejection fraction (LVEF), total
cholesterol, HDL-C, LDL-C and triglyceride. FRS
and CAC score increased signiﬁcantly with increas-
ing extent of CAD (Table 1).
Vascular function and coronary artery disease
Baseline ﬁngertip temperature was not signiﬁcantly
different among the three groups (P = 0.39)
(Table 1; Fig. 2a). Unadjusted DTM indices, TR
and AUC, progressively decreased as the extent of
CAD increased. Similarly, adjusted DTM indices,
aTR and aTMP-AUC, signiﬁcantly decreased from
normal to non-obstructive CAD to obstructive CAD.
Finally, the new DTM index of neurovascular
reactivity, NVR, also decreased with a greater extent
of CAD (Table 1; Fig. 2b–d).
Coronary artery calcium increased in each FRS
category as vascular dysfunction increased; similarly,
in each vascular function category as FRS increased.
The maximum CAC was noted with the combination
of the highest vascular dysfunction and CAC groups
(Fig. 3a).
Extent of CAD increased with increasing CAC and
vascular dysfunction. The most extensive CAD was
observed in the group with maximum CAC and
vascular dysfunction (Fig. 3b).
In linear regression analysis of single variables,
FRS, DTM indices, and CAC were all independent
predictors of obstructive CAD (Table 2a). As shown
in Table 2b, various combination variables of DTM,
FRS, and CAC resulted in higher predictive power
for obstructive CAD. Maximum predictive power
was observed (R-square of 0.52) with the combina-
tion of aTMP-AUC, NVR, CAC and FRS (Table 2b).
Multivariate logistic regression analysis showed
that DTM indices and CAC were each independent
predictors of the extent of CAD (Table 3). Of note,
FRS was not an independent predictor (P = 0.08).
After adjustment for age, gender and conventional
cardiovascular risk factors, the odds ratio of lowest
versus two upper tertiles of aTMP-AUC and NVR
were 5.75 and 1.46 for non-obstructive CAD and
11.62 and 3.58 for obstructive CAD compared to
normal cohorts, respectively (Table 3).
ROC curves were constructed to assess the inde-
pendent as well as incremental diagnostic value of
study variables to predict obstructive CAD. As shown
in Fig. 4, FRS exhibited the lowest area under the
ROC curve (ROC-AUC = 0.65 ± 0.05, 95% CI
0.54–0.76). The addition of DTM indices of vascular
and neurovascular reactivity to FRS progressively
increased the ROC-AUC (aTMP-AUC ? FRS:
ROC-AUC = 0.83 ± 0.03, 95% CI 0.76–0.86)
(aTMP-AUC ? NVR ? FRS: ROC-AUC = 0.88 ±
0.03, 95% CI 0.80–0.95), P = 0.0001 for all. Max-
imum predictive value was observed with the
combination of FRS, aTMP-AUC, NVR, and CAC
(ROC-AUC = 0.94 ± 0.03, 95% CI 0.85–0.98), P =
0.001 compared to FRS alone.
Discussion
The data clearly indicates a strong correlation
between low ﬁngertip temperature rebound measured
by DTM and the presence and extent of CAD
measured by CTA in this symptomatic popula-
tion, independent of age, gender, and traditional
risk factors. These results parallel our previous
Int J Cardiovasc Imaging (2009) 25:725–738 729
123observations in asymptomatic populations that
showed low ﬁngertip temperature rebound measured
by DTM was associated with both risk factors as
measured by FRS and subclinical coronary athero-
sclerosis as measured by CAC [10–12]. Our study
also corroborates an earlier study by Tarjen et al.
Table 1 Cardiovascular risk factors, DTM indices of vascular function, and the extent of CTA-diagnosed coronary artery disease
Normal
N = 28
Non-obstructive CAD
N = 74
Obstructive CAD
N = 27
P value
Age (years) 61 ± 96 4 ± 96 5 ± 10 0.15
Male gender 68% (19) 65% (48) 67% (18) 0.8
Current smoker 18% (5) 16% (12) 18% (5) 0.8
SBP (mm Hg) 134 ± 21 134 ± 20 135 ± 21 0.9
DBP (mm Hg) 75 ± 11 75 ± 12 76 ± 11 0.6
Hypertension
a 82% (23) 84% (62) 89% (24) 0.23
Anti-hypertensive medication 87% (20) 87% (54) 91% (22) 0.57
Total cholesterol (mg/dl) 170 ± 28 172 ± 26 180 ± 26 0.19
HDL-C (mg/dl) 60 ± 16 58.4 ± 15.3 55.1 ± 15.4 0.66
LDL-C (mg/dl) 93.1 ± 28.5 98.9 ± 36.8 91.6 ± 31.4 0.37
Triglycerides (mg/dl) 91 ± 43 85 ± 39 118 ± 37 0.09
Hypercholesterolemia
b 43% (12) 45% (33) 59% (16) 0.06
Cholesterol-lowering medication 83% (10) 85% (28) 81% (13) 0.61
Diabetes mellitus
c 18% (5) 24% (18) 30% (8) 0.13
Family history of CHD
d 32% (9) 34% (25) 37% (10) 0.8
Body mass index (kg/m
2) 29.7 ± 4.1 30.3 ± 4.6 30.4 ± 3.9 0.96
Framingham risk score (%) 11.2 ± 5.9 13.7 ± 6.8 15.1 ± 7.2 0.01
LVEF 63.9 ± 4.9 64.2 ± 3.6 63.5 ± 4.6 0.77
CAC score 0 241 ± 42 720 ± 124 0.0001
Baseline ﬁngertip temperature (C) 29.2 ± 1.8 29.1 ± 1.9 28.1 ± 2.3 0.39
TR 1.05 ± 1.26 0.52 ± 0.85 0.16 ± 0.73 0.01
aTR 1.77 ± 1.18 1.24 ± 1.14 0.94 ± 0.92 0.009
TMP-AUC 272.6 ± 139.2 225.5 ± 152.6 144.9 ± 119.9 0.009
aTMP-AUC 355.6 ± 242.4 277.4 ± 182.4 184.4 ± 171.2 0.001
NVR 161.5 ± 147.4 77.6 ± 88.2 48.8 ± 63.8 0.015
Values presented as mean ± SD or %
NS = Non-signiﬁcant (P[0.05)
LVEF = Left ventricular ejection fraction on CTA
CAC = Coronary artery calcium score
TR = Temperature rebound in the ﬁngertip of the occluded arm
aTR = Adjusted TR
TMP-AUC = Area under the ﬁngertip temperature curve in the occluded arm
aTMP-AUC = Adjusted TMP-AUC
NVR = Area under the ﬁngertip temperature curve in non-occluded arm (neurovascular reactivity)
a Self-reported diagnosis of hypertension, prescribed medication for hypertension, or current blood pressure[140 mmHg systolic or
[90 mmHg diastolic ([130/80 mmHg if diabetic)
b Self-reported diagnosis of high cholesterol, prescribed medication for high cholesterol, or current total cholesterol[200 mg/dl
c Self-reported diagnosis of diabetes (type 1 or 2) or prescribed medication for diabetes
d First degree relative; female\65 years, male\55 years
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123which reported that in patients with chest pain, low
ﬁngertip temperature rebound was strongly associ-
ated with myocardial infarction [9]. Parallel to this
CTA study, our group has also evaluated DTM in
symptomatic patients undergoing myocardial perfu-
sion imaging (MPI) using single photon emission
computed tomography (SPECT) and found a strong
inverse correlation between ﬁngertip temperature
rebound (TR) and abnormal myocardial perfusion,
as measured by summed stress score (SSS) [11].
Vascular reactivity: a vital component
of the circulatory system
Vascular reactivity is a vital component of vascular
function that enables the circulatory system to
respond to physiologic and pharmacologic stimuli
that require adjustments of blood ﬂow and alterations
of vessel tone and diameter [21]. Vascular reactivity
can be exhibited at both the macro-vascular and
micro-vascular levels. ‘‘Macro-vascular’’ pertains to
large, conduit arteries, and ‘‘micro-vascular’’ refers to
small, resistance vessels. Micro-vascular reactivity
causes reactive hyperemia, whereas macro-vascular
reactivity (ﬂow-mediated dilatation or FMD) results
from reactive hyperemia. Both macro- and micro-
vascular reactivity are governed by multiple physio-
logic (endothelium-dependent and -independent) reg-
ulatory mechanisms and are mediated by a number of
biochemical agents, such as nitric oxide (NO),
endothelium-derived hyperpolarizing factor (EDHF),
prostaglandins, adenosine, bradykinin, histamine, and
Fig. 2 Baseline ﬁngertip temperature was not signiﬁcantly
different among the three CAD groups (a). aTR (b) and aTMP-
AUC (c), DTM indices of vascular function proportionally
with the extent of CAD. NVR (d), DTM index of neurovas-
cular reactivity, decreased from mild to moderate to severe
CAD among CTA diagnosed CAD patients
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that macro-vascular reactivity is predominantly med-
iated by endothelium-derived NO, whereas micro-
vascular reactivity is only partially mediated by NO
[21, 24]. Traditionally, assessment of macro-vascular
reactivity (FMD) at the brachial artery level by high
resolution ultrasound imaging has been described as
an endothelial function test [25, 26]. However, some
believe that ‘‘endothelial function’’ is a misnomer
because endothelial cells have numerous functions.
Indeed, endothelial cells exist in all vascular beds,
explaining the common root of vascular disease in
various organs (such as heart, brain, kidney, eyes,
legs, and urogenital) and the close correlation
reported between peripheral and coronary vascular
reactivity [27–29].
Impaired vascular reactivity and atherosclerotic
cardiovascular disease
Previous studies have demonstrated the relationship
between impaired micro- and macro-vascular reac-
tivity and atherosclerotic cardiovascular disease
[29–38]. Similarly, several studies have demon-
strated strong correlations between endothelial-
dependent and independent vascular dysfunction
and cardiovascular risk factors [33]. Nevertheless,
there is a considerable heterogeneity in the magni-
tude of vascular dysfunction in individuals with
similar risk factor proﬁles [29, 39] In this regard,
vascular dysfunction may be seen as an important
‘‘integrative factor’’ of the inherent atherosclerotic
risk of an individual, taking into account the
cumulative effect of various risk and protective
factors [36]. In addition to risk assessment for
prediction of outcomes, another important aspect of
using vascular function is to evaluate response to
therapies [40–45].
In our recent studies of patients receiving treat-
ments, improved vascular function measured by
DTM correlated strongly with the slowed progression
of CAC (r
2 = 0.90, P\0.001) and increased clear-
ance of oxidized phospholipids (Ox-phospholipid/
apoB) (r
2 = 0.81, P\0.001) [46].
Skin vascular and neurovascular reactivity
Skin vascular response is believed to be primarily due
to micro-vascular reactivity; however, it is also
mediated by neurovascular interactions. Numerous
studies have shed light on the pathophysiology of
skin vascular reactivity and its signiﬁcance in patients
with vascular disease [23, 47–51]. Nabel et al. [52]
and Prior et al. [53] have shown that the response of
myocardial blood ﬂow and epicardial coronary arter-
ies to sympathetic stimulation with cold pressor test
is signiﬁcantly different in patients with and without
CAD. Jzerman et al. [54] have found that individuals
at high risk of CAD exhibit impaired micro-vascular
function in skin. Moreover, recent studies have
Fig. 3 a Coronary artery calcium increased by increasing Framingham risk score and vascular dysfunction, b extent of CTA
diagnosed CAD increased with increasing coronary artery calcium and vascular dysfunction
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improved after statin therapy [44, 45, 55].
In our DTM studies, we unexpectedly found
increased ﬁngertip temperature during and after cuff
occlusion in the contra-lateral (non-occluded) arm.
We further conﬁrmed our DTM ﬁndings using
infrared thermal imaging of both hands (see Fig. 1a)
and veriﬁed that increasing ﬁngertip temperature in
the contra-lateral hand during and after cuff occlusion
was indeed due to a cutaneous vasodilative response,
not from artifactual drifts in temperature probes.
Although observations need additional investigations
to elucidate the underlying molecular and cellular
mechanism involved in this phenomenon, we believe
that it is a neurovascular response and may involve
endothelial- or neuronal-nitric oxide synthase (eNOS
Table 2 Linear regression analysis of the relationship between the extent of coronary artery disease diagnosed by CTA and
cardiovascular risk factors (b, 95% CI)
Models RR
2 b 95% CI P value
a: Single variables
II CAC 0.48 0.24 0.49 0.01 to 0.55 0.0001
III TR 0.29 0.11 -0.34 -0.05 to -0.42 0.001
IV aTR 0.32 0.12 -0.39 -0.02 to -0.51 0.001
IV TMP-AUC 0.38 0.14 -0.38 -0.02 to -0.46 0.0001
V aTMP-AUC 0.43 0.18 -0.43 -0.01 to -0.66 0.0001
VI NVR 0.28 0.08 -0.28 -0.001 to -0.46 0.009
b: Combination variables
VII NVR 0.40 0.17 -0.17 -0.001 to -0.45 0.01
?
aTR -0.41 -0.003 to -0.62 0.009
VIII NVR 0.53 0.28 -0.19 -0.001 to -0.43 0.006
?
TMP-AUC -0.45 -0.02 to -0.64 0.0001
IX NVR 0.71 0.51 -0.11 -0.001 to -0.19 0.03
?
aTMP-AUC -0.46 -0.02 to -0.59 0.0001
? 0.0002
CAC 0.36 0.02 to 0.48
X NVR 0.72 0.52 -0.14 0.001 to 0.41 0.03
?
aTMP-AUC -0.47 -0.02 to -0.51 0.0001
?
CAC 0.35 -0.003 to -0.22 0.003
?
FRS 0.12 -0.001 to 0.21 0.2
Dependent variable: CTA diagnosed CAD
FRS = Framingham risk score
CAC = Coronary artery calcium score
TR = Temperature rebound in the ﬁngertip of the occluded arm
aTR = Adjusted TR
TMP-AUC = Area under the ﬁngertip temperature curve in the occluded arm
aTMP-AUC = Adjusted TMP-AUC
NVR = Area under the ﬁngertip temperature curve in non-occluded arm (neurovascular reactivity)
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variate analysis, we found that changes in ﬁngertip
temperature of the non-occluded arm (NVR) was
signiﬁcantly and independently correlated with both
non-obstructive CAD (odd ratio 1.49 (95% CI 1.01–
3.4), P = 0.05) and obstructive CAD (odds ratio 3.61
(95% CI 1.1–11.6), P = 0.009) (Table 3). The higher
the NVR, the likelihood of CAD will be lower.
Vascular dysfunction and CAD in symptomatic
patients
Previous studies showed that impaired vascular
reactivity measured at the macro-vascular level
(brachial artery ﬂow mediated dilation) correlates
with adverse outcomes in patients with chest pain but
without prior CAD [57, 58]. Our study provides new
evidence in addition to those reported by Tarjen et al.
[9] that impaired vascular reactivity measured by
DTM at the skin level (predominantly micro-vascu-
lar) correlates strongly with the presence and extent
of CTA-diagnosed CAD in symptomatic patients
without prior history of cardiovascular disease.
Clinical implications
The appreciation for new screening tests and better
cardiovascular risk assessment of asymptomatic
population who have normal cholesterol has just
increased in light of the JUPITER trial [59]. In this
trial of apparently healthy individuals without
hypercholesterolemia but with elevated high-sensi-
tivity C-reactive protein (Hs-CRP) levels, rosuvast-
atin signiﬁcantly reduced the incidence of major
cardiovascular events. Furthermore, the incidence of
major cardiovascular events increased signiﬁcantly
Table 3 Multivariate logistic regression analysis of the relationship between obstructive coronary artery disease, increased vascular
dysfunction, coronary artery calciﬁcation and Framingham risk score (odds ratio, 95% CI)
Model Normal Non-obstructive CAD Obstructive CAD
Unadjusted
Odds of TR 1 (ref) 4.10 (1.8–12.7), P = 0.005 8.90 (1.9–14.6), P = 0.002
Odds of aTR 1 (ref) 4.23 (1.8–9.5), P = 0.001 10.78 (2.9–24.7), P = 0.001
Odds of TMP-AUC 1 (ref) 5.35 (2.1–9.4), P = 0.0001 10.31 (3.5–17.65), P = 0.0001
Odds of aTMP-AUC 1 (ref) 6.19 (2.4–15.9), P = 0.0001 12.14 (5.5–25.4), P = 0.0001
Odds of NVR 1 (ref) 1.59 (1.05–3.2), P = 0.04 4.69 (1.63–13.5), P = 0.004
Odds of CAC 1 (ref) 6.04 (1.3–18.6), P = 0.0001 11.87 (2.4–20.2), P = 0.0001
Odds of FRS 1 (ref) 1.09 (0.7–1.7), P = 0.74 1.72 (1.0–3.1), P = 0.08
Adjusted for age, gender, diabetes mellitus, hypertension, hypercholesterolemia, family history of CHD, smoking status
Odds of TR 1 (ref) 3.82 (1.1–14.2), P = 0.007 8.51 (1.8–19.6), P = 0.005
Odds of aTR 1 (ref) 3.90 (1.7–7.6), P = 0.001 8.69 (2.6–9.2), P = 0.001
Odds of TMP-AUC 1 (ref) 4.37 (1.7–16.1), P = 0.003 9.61 (3.1–18.1), P = 0.002
Odds of aTMP-AUC 1 (ref) 5.76 (2.1–19.6), P = 0.002 11.63 (5.1–28.5), P = 0.001
Odds of NVR 1 (ref) 1.49 (1.01–3.4), P = 0.05 3.61 (1.1–11.6), P = 0.009
Odds of CAC 1 (ref) 5.62 (1.4–12.8), P = 0.006 10.53 (2.3–25.1), P = 0.002
Odds of FRS 1 (ref) 1.04 (0.6–1.5), P = 0.85 1.69 (0.9–2.9), P = 0.21
Odds of lowest tertile versus two upper tertiles for TR, aTR, TMP-AUC, aTMP-AUC, and NVR; Odds of FRS C20 versus FRS\20;
Odds of CAC C100 versus CAC\100
FRS = Framingham risk score
CAC = Coronary artery calcium score
TR = Temperature rebound in the ﬁngertip of the occluded arm
aTR = Adjusted TR
TMP-AUC = Area under the ﬁngertip temperature curve in the occluded arm
aTMP-AUC = Adjusted TMP-AUC
NVR = Area under the ﬁngertip temperature curve in non-occluded arm (neurovascular reactivity)
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123in apparently healthy subjects with elevated Hs-CRP
in the control group [52]. Although high-sensitive C
reactive protein (hs-CRP) and other markers of
systemic inﬂammation may partly reﬂect the effect
of risk factors on vascular wall, they do not measure
the status of the vascular function. Therefore, direct
assessment of the vascular system is needed. Such a
test must be noninvasive, easy to use and widely
available in order to make a difference in the
primary prevention of atherosclerotic cardiovascular
disease. The strong association between vascular
and neurovascular dysfunction measured by DTM
shown in this study reconﬁrms previous ﬁndings by
our group and others [9–11, 60] and suggests a
potential role for this simple noninvasive test in
evaluation of at risk individuals in addition to risk
factor measurements.
Limitation
The present study has several limitations. Tobacco,
alcohol, caffeine, vasoactive medications, exercise,
high-fat foods, vitamin C, and uncontrolled ambient
temperature can affect vascular function assessment;
however, these were taken into consideration in this
study. Beta blockers which are vasoactive medica-
tions, were administered for heart rates greater than
65 bpm. However, recent studies demonstrated that
concomitant therapy with non-nitrate vasoactive
drugs has no signiﬁcant effect on vascular function
assessment [61]. Because of the cross-sectional
design, we cannot establish causal relationships
between CAD and DTM of vascular reactivity;
however, our ﬁndings support the possibility of a
link between the extent of CAD and the degree of
vascular dysfunction measured by DTM. It is widely
known that even severe vascular dysfunction may be
present even in the absence of ﬂow-limiting epicar-
dial coronary lesions. However, our study demon-
strated that patients with combined severe vascular
dysfunction and increased FRS had a higher likeli-
hood of non-obstructive and obstructive CAD.
Conclusion
Vascular and neurovascular dysfunction measured by
DTM is associated with the presence and extent of
coronary artery disease measured by CTA, indepen-
dent of age, gender and traditional cardiovascular risk
factors. The addition of vascular dysfunction mea-
sured by DTM to the FRS provided incremental value
for the detection of obstructive and non-obstructive
CAD on CTA. Prospective studies are needed to
Fig. 4 ROC curves to assess the diagnostic accuracy of DTM of vascular reactivity and clinical variables for the detection of
obstructive coronary artery disease
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123determine the clinical utility and cost effectiveness of
incorporating DTM in coronary risk assessment.
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